Are patients in heart failure trials representative of primary care populations? A systematic review

Gollop, Nicholas D., Ford, John, Mackeith, Pieter, Thurlow, Caroline, Wakelin, Rachel, Steel, Nicholas ORCID: https://orcid.org/0000-0003-1528-140X and Fleetcroft, Robert (2018) Are patients in heart failure trials representative of primary care populations? A systematic review. BJGP Open, 2 (1). ISSN 2398-3795

Preview

PDF (Accepted manuscript) - Accepted Version Download (278kB) | Preview

Abstract

Background Guidelines recommend drug treatment for patients with heart failure with a reduced ejection fraction (HFrEF), however the evidence for benefit in patients with mild disease, such as most in primary care, is uncertain. Importantly drugs commonly used in heart failure account for one in seven of emergency admissions for adverse drug reactions. Aim To determine to what extent patients included in studies of heart failure treatment with beta blockers, ACE inhibitors and aldosterone antagonists were representative of a typical primary care population with HFrEF in England. Design and Setting Systematic review of RCTs of drug treatment in patients with HFrEF. Method MEDLINE, MEDLINE In-process, EMBASE, and CENTRAL were searched from inception to March 2015. We compared the characteristics of the patient's NYHA classification with a primary care reference population with HFrEF. Results 30 studies were included. Two had incomplete data. None had a 'close match' (<10% deviation from reference study) for NYHA class I disease, 5/28were a close match for NYHA class II, 5/28 for NYHA class III, and 18/28 for NYHA class IV. In general, pre-existing cardiovascular conditions, risk factors and comorbidities were representative of the reference population. Conclusion Patients recruited to studies typically had more severe heart failure than the reference primary care population. When evidence from sicker patients is generalised to less sick people, there is increased uncertainty about benefit and also a risk of harm from overtreatment. More evidence is needed on the effectiveness of treatment of heart failure in asymptomatic patients with NYHA class 1.

Item Type:	Article
Faculty \ School:	Faculty of Medicine and Health Sciences > Norwich Medical School
UEA Research Groups:	Faculty of Medicine and Health Sciences > Research Groups > Health Services and Primary Care Faculty of Medicine and Health Sciences > Research Centres > Population Health
Depositing User:	Pure Connector
Date Deposited:	01 Nov 2017 06:06
Last Modified:	25 Sep 2024 13:05
URI:	https://ueaeprints.uea.ac.uk/id/eprint/65326
DOI:	10.3399/bjgpopen18X101337

Downloads

Actions (login required)

View Item